With targeted bisulfite sequencing of 365 SMA patients, no associations were found between blood-derived DNA methylation and sex, SMN2 copy number, disease severity or treatment response, excluding DNA methylation in SMN2 as an epigenetic biomarker of clinical SMA outcomes. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.